The Mumbai-based firm said in a statement that it has received final approval for its product from the US Food and Drug Administration (USFDA).
The special resolution was approved by the shareholders at the company's annual general meeting held on September 23.
Valuation concerns, FII selling and geopolitical tensions seen as reasons behind the plunge.
Melamine and caprolactum units are operating at full capacity and even other major plants of urea, sulphuric acid and others are functioning more that their capacity, it added.
Saurabh Mukherjea of Ambit Capital said that the key data on Q2 consumption could set the course. If retail and housing finance NPAs are good for Q2, then this cannot be called as a corrective phase.
A strong bearish candle after a Hammer-like formation suggests that markets are likely to remain under pressure for some more time. Short-term weakness is likely to continue towards 9,220 and 9,880 levels, suggest experts.
The company had sought approval for "subscription of equity shares by Autobyte Private Limited in Fifth Gear Ventures Limited resulting in change of control of Fifth Gear Ventures Limited from New Delhi Television Limited and NDTV Convergence Limited to Autobyte Private Limited," NDTV said in a filing to the BSE.
Over the last few years the company has invested significantly to mark the step-wise transition from generics to an innovation-driven organisation, according to the company's annual report.
Speaking about RHFL's listing, Anmol Ambani, executive director of Reliance Capital said, "The listing results in Reliance Capital Shareholders directly owning stake in RHFL, with over 9 lakh shareholders, the largest shareholder base in a housing finance company."
Mahesh Patil of Birla Sun Life believes that the Street currently could be reacting to cues such as higher current account deficit (CAD), pressure on the rupee and developments around fiscal deficit as well.
The company had been hived off from Reliance Capital and investors had received one share of Reliance Home Finance for every share of Reliance Capital held.
L&T, DLF, MRF and Prestige Estates, among others, are being tracked by investors on Friday.
Four promoter entities of the company -- Rakesh Gangwal, Shobha Gangwal, Asha Mukherjee and Chinkerpoo Family Trust -- mopped up Rs 1,265 crore through the institutional placement of shares.
Some experts are not entirely convinced and suggest investors ignore the last minute buying as it could be an early indication of an intermediate top
The online matchmaking services provider listed at its issue price of Rs 985, the higher end of price band.
The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.
In its latest Enforcement Report, United States Food and Drug Administration (USFDA) has said Zydus Pharmaceuticals USA Inc is recalling the Paroxetine tablets in the strength of 30 mg, manufactured by Cadila Healthcare Ltd.
The company has received EIR from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility at Srikakulam unit II, Dr Reddy's said in a filing to BSE.
Rupee movement and price control, among others, could keep a check on pharma. He feels PSU banks could be an arbitrage play.
Markets were largely on the fence ahead of the US Federal Reserve’s FOMC meeting which could see some announcement on the interest rate movement.
The global broking firm also observed that three products, Nuvaring, Suboxone & Copaxone will be major contributors over FY19-20. In fact, the EPS for FY20 could see an upside of 44 percent to Rs 210 if these products are introduced.
The important level to watch put is Monday’s gap of 10115-10131 and a break below this gap could fuel selling pressure, suggest experts.
The next important question in front of traders is – will the rally continue? Well, as long as Nifty trades above 10,137-10,171, the bulls will keep their hold on D-Street. However, a slip below 10,043 could be seen as the first sign of weakness.
Research firm’s upgrade implies 21 percent upside as of Friday’s closing price.
Soon, the stock saw sharp swings, as it fell over a percent in the first few minutes, but has now gained around 4 percent.